Agenus Announces Late-Breaking Oral Presentation at ESMO-GI and Strategies to Advance Botensilimab
Data to be Presented in Heavily Pretreated MSS-CRCSpeed and Innovation Core to Development StrategyReduction of 20% in 2022 Operating CostsLEXINGTON,...